Nektar Therapeutics' drug rezpegaldesleukin is now in phase 3 trials targeting atopic dermatitis, with additional phase 2b data expected in early 2027. The market is optimistic about its potential due to stronger results in atopic dermatitis compared to alopecia areata, where recent updates caused negative reactions. With Galderma's Nemluvio showing peak sales over $2 billion in this space, rezpegaldesleukin's longer-lasting effects could set it apart from competitors. Investors are closely watching upcoming trial results for further validation.
Nektar Therapeutics is the subject of this update, with Pluang providing a snapshot of the health sector as of Oct 30, 2026 20:21 WIB. Among 150 priced health-sector US stocks on Pluang, 71 rose and 76 fell today. Notable movers include AstraZeneca plc (AZN) at USD 183.80 with a 5.39% increase and Maravai LifeSciences Holdings Inc. (MRVI) at USD 7.95 with a 6.03% decrease.
FreightCar America disclosed on October 19, 2026, that it removed 1,285 railcars from its backlog after a customer was unlikely to fulfill contractual obligations, causing its stock to drop 31.4% to $4.02. This sharp decline has led Glancy Prongay Wo...
FirstCash Holdings, Inc. shares fell 14.75% following the October 22, 2026 disclosure of its third quarter financial results, which showed a 28% year-over-year decline in operating income for its American First Finance segment to $33 million. The com...
The global screw compressors market is projected to grow from $13.97 billion in 2026 to $18.38 billion by 2031, at a CAGR of 5.66%. Growth is fueled by rising industrial automation, energy-efficiency regulations, and demand in manufacturing, oil and ...
Enova International's stock fell 23.43% after the company withdrew its application to acquire Grasshopper Bancorp and become a bank holding company. The withdrawal was due to unclear regulatory standards and political pressures cited by Enova. This s...
The global dialysis machines market is forecasted to grow from $17.89 billion in 2026 to $31.54 billion by 2035, at a CAGR of 6.5%. Growth is fueled by rising chronic kidney disease cases, expanding dialysis infrastructure, and innovations like home ...
